Correct Answer: D. Medullary thyroid carcinoma
Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy arising from parafollicular C cells of the thyroid. The histopathology findings are pathognomonic: TTF-1 positivity confirms thyroid origin, while synaptophysin and chromogranin positivity establish neuroendocrine differentiation—C cells are neuroendocrine cells. The critical discriminator is amyloid deposition, which is virtually diagnostic of MTC. This amyloid is composed of calcitonin, the hormone secreted by C cells. MTC accounts for 3–5% of thyroid cancers in India and presents with a neck mass, dysphagia, and dyspnea due to local invasion. Calcitonin and carcinoembryonic antigen (CEA) are tumor markers. MTC can occur sporadically (75%) or as part of MEN 2A/2B syndromes (25%), necessitating RET proto-oncogene testing and family screening. The amyloid finding is the key that separates MTC from all other thyroid malignancies, which do not produce calcitonin-derived amyloid.
Why the other options are wrong
A. Follicular thyroid carcinoma — Follicular carcinoma is TTF-1 positive but lacks neuroendocrine markers (synaptophysin and chromogranin are negative) and does not produce amyloid. It arises from follicular epithelium, not C cells. Histology shows follicular architecture without neuroendocrine differentiation. This option may trap students who focus only on TTF-1 positivity without integrating the neuroendocrine immunophenotype. B. Anaplastic thyroid carcinoma — Anaplastic carcinoma is highly aggressive and TTF-1 positive, but it is not a neuroendocrine tumor—synaptophysin and chromogranin are typically negative. It lacks amyloid deposition entirely. Histologically, it shows spindle cells, giant cells, and marked pleomorphism, not the neuroendocrine features seen here. The presence of neuroendocrine markers rules this out definitively. C. Papillary thyroid carcinoma — Papillary carcinoma is TTF-1 positive but lacks neuroendocrine differentiation—synaptophysin and chromogranin are negative. It does not produce amyloid. Histology shows papillary architecture with characteristic nuclear grooves and pseudoinclusions. The combination of synaptophysin, chromogranin, and amyloid deposition is incompatible with papillary carcinoma, making this a clear distractor.
High-Yield Facts
- Amyloid deposition in thyroid tumors is virtually pathognomonic for medullary carcinoma (calcitonin-derived amyloid).
- Synaptophysin and chromogranin positivity indicate neuroendocrine differentiation; only MTC among thyroid cancers shows this pattern.
- TTF-1 is positive in all thyroid carcinomas (follicular, papillary, medullary, anaplastic); it is not discriminatory—use it with other markers.
- Calcitonin and CEA are tumor markers for MTC; elevated calcitonin is diagnostic and used for surveillance post-thyroidectomy.
- MEN 2A/2B association: 25% of MTC cases are hereditary; RET testing and family screening are mandatory in all MTC patients.
- C-cell origin distinguishes MTC from follicular-derived cancers; C cells are neuroendocrine and produce calcitonin.
Mnemonics
MTC = C cells + Calcitonin + Chromogranin Medullary carcinoma arises from C cells (parafollicular), secretes Calcitonin (forms amyloid), and is Chromogranin/synaptophysin positive. Use this when you see neuroendocrine markers in a thyroid tumor. AMYLOID in thyroid = MTC until proven otherwise Amyloid deposition in thyroid histology is the red flag for medullary carcinoma. No other thyroid malignancy produces calcitonin-derived amyloid. This is the single most discriminatory finding.
NBE Trap
NBE pairs TTF-1 positivity across all thyroid cancers to lure students into choosing follicular or papillary carcinoma. The trap is solved by recognizing that neuroendocrine markers (synaptophysin, chromogranin) + amyloid are unique to MTC—TTF-1 alone is insufficient for diagnosis.
Clinical Pearl
In Indian clinical practice, MTC screening via serum calcitonin is increasingly recommended in all thyroid cancer patients because 25% are hereditary (MEN 2A/2B). A single elevated calcitonin level warrants RET testing and cascade family screening—early detection of hereditary MTC in relatives can be lifesaving through prophylactic thyroidectomy before age 5 in MEN 2B.
_Reference: Robbins Ch. 8 (Endocrine System); Harrison Ch. 375 (Thyroid Carcinoma); KD Tripathi Ch. 32 (Thyroid Hormones and Antithyroid Drugs)_